Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition

Rheumatology

Volumn 41, Issue 9, 2002, Pages 965-971

  Maddison, P ^a,b  

^a BANGOR UNIVERSITY   (United Kingdom)

^b YSBYTY GWYNEDD   (United Kingdom)

Author keywords

ACE inhibition; Autoantibodies; Disease activity; Scleroderma

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; ILOPROST; KETANSERIN; PROSTACYCLIN DERIVATIVE; QUINAPRIL; SEROTONIN ANTAGONIST;

BLOOD VESSEL INJURY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DRUG FORMULATION; DRUG INDUSTRY; FINANCIAL MANAGEMENT; GENETIC HETEROGENEITY; HUMAN; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL SOCIETY; MULTICENTER STUDY; PATHOGENESIS; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; REGISTER; REVIEW; SCLERODERMA; UNITED KINGDOM;

EID: 0036733462     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/41.9.965     Document Type: Review

References (57)

1. Scleroderma and related disorders in adults and children
2. Mortality from scleroderma in England and Wales 1968-1975
3. How can treatment of systemic sclerosis be improved? By setting up a national database of all cases and entering patients into trials
4. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
5. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis
6. Characterisation of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives
7. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: A six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting
8. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease
9. Molecular structure and function of autoantigens in systemic sclerosis. Int Rev Immunol
10. Gastrointestinal motility disorders in scleroderma
11. Limited scleroderma is associated with increased prevalence of macrovascular disease
12. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis
13. Systemic sclerosis: Current pathogenetic concepts and future prospects for targeted therapy
14. A brief overview of the pathogenesis of scleroderma (systemic sclerosis)
15. Raynaud's phenomenon and scleroderma: Dysregulated neuroendothelial control of vascular tone
16. Current options for the treatment of systemic scleroderma
17. Infusion of iloprost, a prostacyclin analogue, for the treatment of Raynaud's phenomenon in systemic sclerosis
18. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose comparison study
19. Successful medical treatment of scleroderma renal crisis
20. Angiotensin converting enzyme inhibitors in Raynaud's phenomenon
21. Comparative assessment of the effects of vasodilators on peripheral vascular reactivity in patients with systemic scleroderma and Raynaud's phenomenon: Color Doppler flow imaging study
22. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin-converting enzyme (ACE) inhibitors
23. Autoantibody reactive with RNA polymerase III in systemic sclerosis
24. Survival with systemic sclerosis (scleroderma): A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients
25. The management of renal scleroderma: Experience with dialysis, nephrectomy and transplantation
26. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structional and functional abnormalities of the renal cortical circulation
27. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade
28. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
29. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients
30. Serum rennin and rennin substrate levels in scleroderma
31. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease
32. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension
33. Non-invasive evaluation of long-term cardiac effects of captopril in systemic sclerosis
34. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis
35. Angiotensin converting enzyme inhibitors in Raynaud's phenomenon
36. A randomised double-blind crossover investigation of treatment of Raynaud's disease with captopril
37. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon
38. Enalapril in Raynaud's phenomenon
39. Subjective and objective assessment of enalapril in primary Raynaud's phenomenon
40. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
41. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
42. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
43. Remodelling of myocardium and arteries by chronic angiotensin converting enzyme inhibition of hypertensive patients
44. ACE-inhibition with quinapril improves endothelial function in patients with chronic heart failure due to increased availability of nitric oxide: Potential role of affinity to tissue ACE
45. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon
46. A comparative study of four anti-hypertensive agents on endothelial function in patients with coronary disease
47. Assessing patients with lupus: Towards a drug responder index
48. European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials
49. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI)
50. Assessment of construct validity of the European Scleroderma Study Group (EssSG) activity criteria for systemic sclerosis
51. Reliability of skin involvement measures in scleroderma
52. Ultrasonic measurement of skin thickness in patients with systemic sclerosis
53. A disease severity scale for systemic sclerosis: Development and testing
54. Correlates of the disability index of the health assessment questionnaire
55. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ)
56. Assessment of damage and activity in systemic sclerosis
57. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and systemic sclerosis